SecBot SecBot

VANI

Vivani Medical, Inc.
Nasdaq· Electromedical & Electrotherapeutic Apparatus· Inc. DE· CIK 0001266806 Healthcare & Medical Devices
$1.13 +0.02 (+1.80%)
Oct 26 4:00 PM ET · prev $1.11
Market cap
$98.3M
Micro cap
Median target
$4.00
+254% · range $3.50–4.00
Next earnings
Nov 18
in 23 days · EPS est. −$0.09
1 year
−30.2%
from $1.62 · Oct 27
30 days
−9.6%
from $1.25
52-week range
$0.9380–1.77
−36% from high · low Mar 30
Avg volume 20D
150.4K
shares / day
Short interest
519.7K
≈0.6% of shares · −25.1%
Days to cover
2.6
at average volume
Insider net
+$10.7M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 18, 2026
Strongest BEARISH Vivani Medical filed a 424B5 prospectus supplement registering up to 3,947,368 shares of common stock for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $10.7M at an average $1.19. No open-market sales.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 5 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.090 → −$0.090 over 90 days.

  • Short sellersCOVERING

    Short interest −25.1% to 519.7K shares. 2.6 days to cover, ≈0.6% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT51,108$63.4K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM28,346$35.1K
MARSHALL WACE, LLPNEAR_EXIT11,161$13.8K
FMR LLCNEAR_EXIT142$176.00
MORGAN STANLEYNEAR_EXIT10$12.00
GEODE CAPITAL MANAGEMENT, LLCADD600,578$600.7K
TUDOR INVESTMENT CORP ET ALTRIM426,302$426.3K
UBS Group AGDOUBLED337,749$337.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +254%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jun 23, 2026Lake Street
INITIATE
INITIATEBuy

Insider ledger

Form 4
$10.7M
bought · 1 insider
$0
sold · 0 insiders
−4.7%
vs their $1.19 cost
DateInsiderTypeValue
Oct 15, 2026
Mendelsohn Aaron
Director
GIFT20,000 sh
Jul 28, 2026
Mendelsohn Adam
Chief Executive Officer
AWARD200,000 sh
Jul 28, 2026
Mendelsohn Adam
Chief Executive Officer
AWARD100,000 sh
Jul 28, 2026
Le Truc
Chief Operations Officer
AWARD160,000 sh
Jul 28, 2026
Le Truc
Chief Operations Officer
AWARD80,000 sh
Jul 28, 2026
Baldor Anthony
Chief Financial Officer
AWARD75,000 sh
Jul 28, 2026
Baldor Anthony
Chief Financial Officer
AWARD37,500 sh
Jul 28, 2026
Dwyer Donald
Chief Business Officer
AWARD70,000 sh

Earnings setup

Estimates
Nov 18
reports in 23 days
−$0.09
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.09-$0.09–-$0.09-8.0%$0.00
Next Q-$0.09-$0.09–-$0.09-3.8%$0.00
Current FY-$0.33-$0.33–-$0.33+2.0%$0.00
Next FY-$0.39-$0.54–-$0.27+10.6%$0.00

Short side

FINRA· Sep 30, 2026
519,687
shares short
-25.1%
vs prior settlement
2.6
days to cover
≈0.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Insider
Mendelsohn Aaron gifted 20,000 shares
Director
Sep 25, 2026 SEC
Vivani Medical filed a 424B5 prospectus supplement registering up to 3,947,368 shares of common stock for resale by…
424B5 — Impact 5/10
Aug 18, 2026 Earnings calendar
VANI Q2 2026 Earnings Scheduled — 2026-08-18
Aug 17, 2026 SEC
Vivani Medical filed an 8-K under Item 7.01 to furnish a routine investor slide presentation dated August 17, 2026…
8-K — Impact 3/10
Jul 28, 2026 Insider
Mendelsohn Adam was granted 200,000 shares
Chief Executive Officer
Jul 28, 2026 Insider
Mendelsohn Adam was granted 100,000 shares
Chief Executive Officer
Jul 16, 2026 SEC
Vivani Medical disclosed via an 8-K that its CEO presented at the Emerging Growth Conference, updating that first…
8-K — Impact 3/10
Jul 2, 2026 Press
{ "summary": "Vivani Medical announced a definitive agreement to merge its wholly owned subsidiary Cortigent into…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
VANI Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Aug 18, 2026
Earnings date
VANI Q2 2026 Earnings Scheduled — 2026-08-18
Aug 6, 2026
Press release
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.
Jul 2, 2026
M&A
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company’s name and…
Jun 26, 2026
Press release
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage…
Jun 25, 2026
FDA
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage…

SecBot reports

6 filings · 2 press releases · 1 bullish · 1 bearish · 4 neutral
All VANI filing & press-release reports (8)